|
Announcing Amgen’s CodeBreaK oncology clinical trials website.
 |
| Amgen Oncology is expanding the virtual reach of the CodeBreaK clinical trials with the launch of a new website. |
|
CodeBreaK clinical trials are currently recruiting patients with advanced non-small cell lung cancer (NSCLC) and other advanced solid tumors whose cancer contains the KRAS G12C genetic mutation. The new website introduces patients and their loved ones to the CodeBreaK clinical trials and the study drug, sotorasib (the proposed generic name for AMG 510), and encourages them to contact us to learn more. We hope you will explore the CodeBreaK website and help spread the word.
Sincerely,
The CodeBreaK Team
|
|
